Guardant Health (NASDAQ:GH) Earns Buy Rating from Analysts at Craig Hallum

Craig Hallum began coverage on shares of Guardant Health (NASDAQ:GH) in a research report sent to investors on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $28.00 price target on the stock.

Several other brokerages have also issued reports on GH. The Goldman Sachs Group decreased their target price on Guardant Health from $32.00 to $28.00 and set a buy rating for the company in a research report on Monday, April 15th. JPMorgan Chase & Co. decreased their target price on Guardant Health from $60.00 to $45.00 and set an overweight rating for the company in a research report on Friday, February 23rd. Guggenheim reaffirmed a neutral rating on shares of Guardant Health in a research report on Friday, April 5th. Canaccord Genuity Group decreased their target price on Guardant Health from $50.00 to $45.00 and set a buy rating for the company in a research report on Friday, February 23rd. Finally, Piper Sandler decreased their price objective on Guardant Health from $40.00 to $30.00 and set an overweight rating for the company in a report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Guardant Health has an average rating of Moderate Buy and a consensus target price of $39.27.

Guardant Health Price Performance

NASDAQ GH opened at $17.35 on Wednesday. The business has a fifty day simple moving average of $18.84 and a 200 day simple moving average of $22.96. Guardant Health has a 12 month low of $15.81 and a 12 month high of $41.06. The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). The company had revenue of $155.05 million during the quarter, compared to analysts’ expectations of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. As a group, equities research analysts expect that Guardant Health will post -3.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Kumud Kalia bought 2,187 shares of the business’s stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the purchase, the insider now directly owns 12,722 shares in the company, valued at $226,706.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.20% of the stock is owned by corporate insiders.

Institutional Trading of Guardant Health

A number of large investors have recently modified their holdings of GH. CWM LLC boosted its position in shares of Guardant Health by 137.1% during the 3rd quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after acquiring an additional 569 shares during the last quarter. AE Wealth Management LLC purchased a new position in shares of Guardant Health during the 3rd quarter valued at about $572,000. SG Americas Securities LLC purchased a new position in shares of Guardant Health during the 3rd quarter valued at about $818,000. Handelsbanken Fonder AB raised its holdings in shares of Guardant Health by 7.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 122,441 shares of the company’s stock valued at $3,629,000 after buying an additional 8,341 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its holdings in shares of Guardant Health by 81.1% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 25,684 shares of the company’s stock valued at $761,000 after buying an additional 11,498 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.